Rising Cancer Prevalence to Drive the US Personalized Cancer Sequencing Market

Wednesday 3 October 2012, Amsterdam

A new research report reveals that despite burgeoning efforts by the US health authorities, cancer incidence rates in the US are on rise. The country is likely to witness around 577,190 deaths from cancer in 2012. If the current trend persists, this number is likely to reach around 592,300 by 2016, taking the total prevalence to a staggering figure of 21.2 Million. Further, California leads in terms of total number of new cases followed by Florida, Texas, and New York. California, in 2012, is expected to witness around 165,810 new cases of cancer mainly in female breast, prostate, lung & bronchus and colon & rectum.

These figures pose serious challenges for the US Government and offers immense opportunities for the players that offer personalized cancer whole genome sequencing (WGS). Personalized diagnosis of patient's genome facilitates personalized cancer treatment and saves on unnecessary drug-related complications and costs, making it an attractive option for both the patient and health care provider. This sector thus stands a responsibility of catering to a huge population of cancer patients that present a soaring potential market.

The report entitled "US Personalized Cancer Genome Sequencing Market" provides an extensive research and in-depth analysis of the current status and expected position of the US market for personalized WGS intended for diagnosing cancer. It evaluates the current status and future potential of the market and focuses on the strengths and weaknesses of the market players.

Moreover, the report projects the future size of the market till 2016. In this context, it illustrates the market drivers, key developments, and restraints that may impact the market in an effective manner. A brief description of the regulatory environment has also been provided.